Abstract
Purpose: Hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined nonluminal subtypes, particularly the HER2-enriched (HER2-E) and basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting. Patients and Methods: The SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2− mBC classified as HER2-E or basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-E or basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m2 weekly). Results: The primary endpoint, overall response rate (ORR), was 61.1% [95% confidence interval (CI), 35.7–82.7], and the clinical benefit rate was 94.4% (95% CI, 72.7–99.9). The median progression-free survival was 8.1 months (95% CI, 5.9–10.4), and the median overall survival was 26 months [95% CI, 18−not reached (NR)]. Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, whereas luminal-related gene expression was associated with lower clinical benefit. Conclusions: These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined nonluminal subtypes of HR+/HER2− mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post–endocrine treatment decisions.
Funding Information
  • HORIZON EUROPE Marie Sklodowska-Curie Actions (955951)
  • Fundación Científica Asociación Española Contra el Cáncer (INVES21943BRAS)
  • Fundación Científica Asociación Española Contra el Cáncer (EPAEC246711CLIN)
  • Fundación Fero (ONCOXXI21)
  • CRIS Cancer Foundation (PR_EX_2021-14)
  • Instituto de Salud Carlos III (PI22/01017)
  • Breast Cancer Research Foundation (BCRF-22-198)
  • Breast Cancer Research Foundation (BCRF-23-198)
  • Breast Cancer Research Foundation (BCRF-24-198)
  • Horizon 2020 Framework Programme (847912)

This publication has 49 references indexed in Scilit: